28 April 2026
Brazil's ANVISA Gambit: Decoding the 2027 MedTech Agenda | Pure Global Insights
LATAM MedTech Insights
About
Brazil's regulatory body, ANVISA, has just released its strategic agenda for 2026-2027, signaling the most significant shift in the country's MedTech landscape in years. This isn't just a routine update; it's a complete overhaul of key regulations that will redefine market access for international medical device companies. For prepared firms, this opens the door to streamlined entry into Latin America's largest market. For the unprepared, it could mean being locked out entirely.
We dive deep into the specifics, moving beyond the headlines to analyze the real-world impact of these changes. We uncover the hidden opportunities and critical threats buried in the new agenda, focusing on the upcoming revolution in Software as a Medical Device (SaMD) rules and the game-changing proposal to make MDSAP certification mandatory.
**Key Questions Answered in This Episode:**
* What does ANVISA's new agenda mean for my Software as a Medical Device (SaMD) product?
* Is mandatory MDSAP participation coming to Brazil, and how should my company prepare?
* How will changes to Good Manufacturing Practice certificate validity affect my registration renewals?
* Are the new regulations creating a faster path to market or a higher wall for entry?
* How can I align my global regulatory strategy with Brazil's push for international harmonization?
* What are the three most critical action items my team should focus on in the next quarter?
* Could these changes make Brazil a more predictable market than other LATAM countries?
Struggling to decode ANVISA's new agenda? Pure Global offers end-to-end regulatory consulting to turn these challenges into opportunities. With local experts in Brazil and advanced AI tools, we streamline your market access strategy, manage technical dossier submissions, and act as your official in-country representative. Don't let regulatory complexity block your entry into Latin America's powerhouse market. Contact us for a strategic assessment at info@pureglobal.com or visit https://pureglobal.com/.
We dive deep into the specifics, moving beyond the headlines to analyze the real-world impact of these changes. We uncover the hidden opportunities and critical threats buried in the new agenda, focusing on the upcoming revolution in Software as a Medical Device (SaMD) rules and the game-changing proposal to make MDSAP certification mandatory.
**Key Questions Answered in This Episode:**
* What does ANVISA's new agenda mean for my Software as a Medical Device (SaMD) product?
* Is mandatory MDSAP participation coming to Brazil, and how should my company prepare?
* How will changes to Good Manufacturing Practice certificate validity affect my registration renewals?
* Are the new regulations creating a faster path to market or a higher wall for entry?
* How can I align my global regulatory strategy with Brazil's push for international harmonization?
* What are the three most critical action items my team should focus on in the next quarter?
* Could these changes make Brazil a more predictable market than other LATAM countries?
Struggling to decode ANVISA's new agenda? Pure Global offers end-to-end regulatory consulting to turn these challenges into opportunities. With local experts in Brazil and advanced AI tools, we streamline your market access strategy, manage technical dossier submissions, and act as your official in-country representative. Don't let regulatory complexity block your entry into Latin America's powerhouse market. Contact us for a strategic assessment at info@pureglobal.com or visit https://pureglobal.com/.